Ipca Laboratories Share Price
Sector: Biotechnology & Drugs
1437.45 +44.95 (3.23%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1390.40
Today’s High
1460.60
52 Week Low
1060.95
52 Week High
1757.65
1436.80 +44.20 (3.17%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
1393.60
Today’s High
1464.10
52 Week Low
1052.00
52 Week High
1755.90
Key Metrics
- Market Cap (In Cr) 36448.87
- Beta 0.6
- Div. Yield (%) 0.29
- P/B 5.58
- TTM P/E 58.95
- Peg Ratio -2.23
- Sector P/E 24.5
- Open Price 1390.4
- Prev Close 1392.5
Ipca Laboratories Analysis
Price Analysis
-
1 Week2.26%
-
3 Months-4.87%
-
6 Month-9.37%
-
YTD-17.85%
-
1 Year8.16%
Risk Meter
- 37% Low risk
- 37% Moderate risk
- 37% Balanced Risk
- 37% High risk
- 37% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 4
- 4
- 4
- 4
- Buy
- 6
- 6
- 6
- 6
- Hold
- 3
- 3
- 3
- 3
- Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Strong Sell
- 0.00
- 0.00
- 0.00
- 0.00
- Total
- 13
- 13
- 13
- 13
Ipca Laboratories News
As the world rethinks China, these Indian stocks are already one step ahead
8 min read . 16 Apr 2025Nifty Pharma slumps 6% as Donald Trump says pharma tariffs coming soon
2 min read . 04 Apr 2025Buy Balrampur Chini, V-Guard, Ipca Lab, suggests Rupak De in a weak market today
3 min read . 01 Apr 2025Nifty Pharma drops 2%; 19 index stocks tumble up to 7%. What's behind the fall?
1 min read . 10 Feb 2025Ipca Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 7705.04
- Selling/ General/ Admin Expenses Total
- 3160.38
- Depreciation/ Amortization
- 357.24
- Other Operating Expenses Total
- 81.32
- Total Operating Expense
- 6949.47
- Operating Income
- 755.57
- Net Income Before Taxes
- 842.67
- Net Income
- 547.35
- Diluted Normalized EPS
- 25.85
- Period
- 2024
- Total Assets
- 11101.28
- Total Liabilities
- 4769.09
- Total Equity
- 6332.19
- Tangible Book Valueper Share Common Eq
- 240.4
- Period
- 2024
- Cashfrom Operating Activities
- 1021.15
- Cashfrom Investing Activities
- -1291.79
- Cashfrom Financing Activities
- -552.55
- Net Changein Cash
- -823.19
- Period
- 2023
- Total Revenue
- 6244.32
- Selling/ General/ Admin Expenses Total
- 2474.11
- Depreciation/ Amortization
- 261.56
- Other Operating Expenses Total
- 31.65
- Total Operating Expense
- 5544.76
- Operating Income
- 699.56
- Net Income Before Taxes
- 745.29
- Net Income
- 471.32
- Diluted Normalized EPS
- 18.23
- Period
- 2023
- Total Assets
- 8626.43
- Total Liabilities
- 2784.41
- Total Equity
- 5842.02
- Tangible Book Valueper Share Common Eq
- 222.49
- Period
- 2023
- Cashfrom Operating Activities
- 805.81
- Cashfrom Investing Activities
- -725
- Cashfrom Financing Activities
- 507.24
- Net Changein Cash
- 588.05
- Period
- 2022
- Total Revenue
- 5829.79
- Selling/ General/ Admin Expenses Total
- 2092.32
- Depreciation/ Amortization
- 232.42
- Other Operating Expenses Total
- 23.76
- Total Operating Expense
- 4771.44
- Operating Income
- 1058.35
- Net Income Before Taxes
- 1114.56
- Net Income
- 884.08
- Diluted Normalized EPS
- 35.21
- Period
- 2022
- Total Assets
- 7623.53
- Total Liabilities
- 2158.69
- Total Equity
- 5464.84
- Tangible Book Valueper Share Common Eq
- 207.28
- Period
- 2022
- Cashfrom Operating Activities
- 860.16
- Cashfrom Investing Activities
- -855.05
- Cashfrom Financing Activities
- 426.81
- Net Changein Cash
- 431.92
- Period
- 2021
- Total Revenue
- 5419.99
- Selling/ General/ Admin Expenses Total
- 1788.86
- Depreciation/ Amortization
- 209.17
- Other Operating Expenses Total
- 19.79
- Total Operating Expense
- 4122.44
- Operating Income
- 1297.55
- Net Income Before Taxes
- 1381.28
- Net Income
- 1140.01
- Diluted Normalized EPS
- 45.7
- Period
- 2021
- Total Assets
- 6068.36
- Total Liabilities
- 1366.71
- Total Equity
- 4701.65
- Tangible Book Valueper Share Common Eq
- 178.98
- Period
- 2021
- Cashfrom Operating Activities
- 1090.13
- Cashfrom Investing Activities
- -520.69
- Cashfrom Financing Activities
- -305.82
- Net Changein Cash
- 263.62
- Period
- 2020
- Total Revenue
- 4648.71
- Selling/ General/ Admin Expenses Total
- 1713.32
- Depreciation/ Amortization
- 210.5
- Other Operating Expenses Total
- 12.81
- Total Operating Expense
- 3935.39
- Operating Income
- 713.32
- Net Income Before Taxes
- 738.89
- Net Income
- 606.32
- Diluted Normalized EPS
- 24.66
- Period
- 2020
- Total Assets
- 5259.83
- Total Liabilities
- 1632.35
- Total Equity
- 3627.48
- Tangible Book Valueper Share Common Eq
- 135.68
- Period
- 2020
- Cashfrom Operating Activities
- 564.58
- Cashfrom Investing Activities
- -509.65
- Cashfrom Financing Activities
- -130.46
- Net Changein Cash
- -75.53
- Period
- 2019
- Total Revenue
- 3773.18
- Selling/ General/ Admin Expenses Total
- 1533.82
- Depreciation/ Amortization
- 182.42
- Other Operating Expenses Total
- 12.16
- Total Operating Expense
- 3243.51
- Operating Income
- 529.67
- Net Income Before Taxes
- 546.46
- Net Income
- 444.83
- Diluted Normalized EPS
- 17.65
- Period
- 2019
- Total Assets
- 4550.67
- Total Liabilities
- 1428.28
- Total Equity
- 3122.39
- Tangible Book Valueper Share Common Eq
- 114.69
- Period
- 2019
- Cashfrom Operating Activities
- 492.28
- Cashfrom Investing Activities
- -156.31
- Cashfrom Financing Activities
- -183.2
- Net Changein Cash
- 152.77
- Period
- 2024-12-31
- Total Revenue
- 2245.37
- Selling/ General/ Admin Expenses Total
- 485.44
- Depreciation/ Amortization
- 98.46
- Other Operating Expenses Total
- 628.64
- Total Operating Expense
- 1880.75
- Operating Income
- 364.62
- Net Income Before Taxes
- 367.92
- Net Income
- 248.14
- Diluted Normalized EPS
- 9.78
- Period
- 2024-12-31
- Period
- 2024-12-31
- Period
- 2024-09-30
- Total Revenue
- 2354.9
- Selling/ General/ Admin Expenses Total
- 509.84
- Depreciation/ Amortization
- 100.35
- Other Operating Expenses Total
- 645.02
- Total Operating Expense
- 2013.77
- Operating Income
- 341.13
- Net Income Before Taxes
- 344.83
- Net Income
- 229.48
- Diluted Normalized EPS
- 9.05
- Period
- 2024-09-30
- Total Assets
- 11423.77
- Total Liabilities
- 4723.38
- Total Equity
- 6700.39
- Tangible Book Valueper Share Common Eq
- 254.99
- Period
- 2024-09-30
- Cashfrom Operating Activities
- 739.59
- Cashfrom Investing Activities
- -300.8
- Cashfrom Financing Activities
- -336.34
- Net Changein Cash
- 102.45
- Period
- 2024-06-30
- Total Revenue
- 2092.63
- Selling/ General/ Admin Expenses Total
- 487.87
- Depreciation/ Amortization
- 98.89
- Other Operating Expenses Total
- 568.55
- Total Operating Expense
- 1798.8
- Operating Income
- 293.83
- Net Income Before Taxes
- 290.39
- Net Income
- 192.24
- Diluted Normalized EPS
- 7.58
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2033.01
- Selling/ General/ Admin Expenses Total
- 466.01
- Depreciation/ Amortization
- 98.13
- Other Operating Expenses Total
- 520.17
- Total Operating Expense
- 1945.96
- Operating Income
- 87.05
- Net Income Before Taxes
- 76.6
- Net Income
- 59.59
- Diluted Normalized EPS
- 6.85
- Period
- 2024-03-31
- Total Assets
- 11101.28
- Total Liabilities
- 4769.09
- Total Equity
- 6332.19
- Tangible Book Valueper Share Common Eq
- 240.4
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1021.15
- Cashfrom Investing Activities
- -1291.79
- Cashfrom Financing Activities
- -552.55
- Net Changein Cash
- -823.19
- Period
- 2023-12-31
- Total Revenue
- 2052.86
- Selling/ General/ Admin Expenses Total
- 459.04
- Depreciation/ Amortization
- 99.5
- Other Operating Expenses Total
- 565.54
- Total Operating Expense
- 1821.03
- Operating Income
- 231.83
- Net Income Before Taxes
- 288.89
- Net Income
- 179.88
- Diluted Normalized EPS
- 6.99
- Period
- 2023-12-31
- Period
- 2023-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Ipca Laboratories Technical
Moving Average
SMA
- 5 Day1399.14
- 10 Day1383.7
- 20 Day1400.99
- 50 Day1385.37
- 100 Day1463.01
- 300 Day1470.11
Ipca Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Glenmark Pharmaceuticals
- 1438.5
- -8.8
- -0.61
- 1830.05
- 985.6
- 40687.35
- Biocon
- 341.5
- 2
- 0.59
- 404.6
- 270
- 41000.49
- Ipca Laboratories
- 1437.45
- 44.95
- 3.23
- 1757.65
- 1060.95
- 36448.87
- Laurus Labs
- 608.3
- 5.4
- 0.9
- 660.9
- 386.85
- 32802.73
- Ajanta Pharma
- 2632.35
- 29.9
- 1.15
- 3485.75
- 2022.05
- 32888.19
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Glenmark Pharmaceuticals
- -
- 5.21
- 1.61
- 1.43
- Biocon
- 43.24
- 1.88
- 5.73
- 8.83
- Ipca Laboratories
- 53.87
- 5.58
- 14.98
- 12.25
- Laurus Labs
- 90.82
- 7.27
- 18.12
- 11.88
- Ajanta Pharma
- 35.41
- 8.58
- 22.49
- 19.6
Ipca Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 29-May-25
- Audited Results & Final Dividend
- 13-Feb-25
- Quarterly Results
- 14-Nov-24
- Quarterly Results & Interim Dividend
- 30-Sept-24
- Others
- 13-Aug-24
- Quarterly Results
- 29-May-24
- Audited Results & Final Dividend
- 14-Feb-24
- Quarterly Results
- 10-Nov-23
- Quarterly Results & Interim Dividend
- 10-Aug-23
- Quarterly Results
- 29-May-23
- Audited Results
- Meeting Date
- Announced on
- Purpose
- 13-Aug-24
- 18-Jul-24
- AGM
- 30-Mar-24
- 23-Feb-24
- POM
- 10-Aug-23
- 29-May-23
- AGM
- 31-Mar-23
- 24-Feb-23
- POM
- 02-Sept-21
- 04-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 24-Oct-24
- 25-Nov-24
- 25-Nov-24
- 2
- 29-May-24
- -
- 06-Aug-24
- 2
- 26-Oct-23
- 22-Nov-23
- 22-Nov-23
- 2
- 02-Nov-22
- 23-Nov-22
- 22-Nov-22
- 4
- 20-Oct-21
- 23-Nov-21
- 22-Nov-21
- 8

- Ex-Splits
- Old FV
- New FV
- Description
- 10-Jan-22
- 2
- 1
- Stock split from Rs. 2/- to Re. 1/-.
